Literature DB >> 29527624

Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning.

Buranee Kanchanatawan1, Sira Sriswasdi2, Supaksorn Thika1, Sunee Sirivichayakul3, André F Carvalho4, Michel Geffard5,6, Marta Kubera7, Michael Maes8,9,10.   

Abstract

Deficit schizophrenia is characterized by neurocognitive impairments and changes in the patterning of IgA/IgM responses to plasma tryptophan catabolites (TRYCATs). In the current study, supervised pattern recognition methods, including logistic regression analysis (LRA), Support Vector Machine (SVM), and Soft Independent Modeling of Class Analogy (SIMCA), were used to examine whether deficit schizophrenia is a discrete diagnostic class with respect to Consortium To Establish a Registry for Alzheimer's disease (CERAD) and Cambridge Neuropsychological Test Automated Battery (CANTAB) tests and IgA/IgM responses to noxious (NOX) and generally more protective (PRO) TRYCATs. We recruited patients with (n = 40) and without (n = 40) deficit schizophrenia and healthy volunteers (n = 40). The combined use of TRYCAT and CERAD features strongly segregates deficit from nondeficit schizophrenia and healthy controls. Three out of the top five most important features in LRA, SVM and SIMCA agreed, namely two different NOX/PRO TRYCAT ratios and false memory recall. SIMCA shows that deficit schizophrenia is significantly separated from nondeficit schizophrenia and controls with as top 6 features IgA responses to picolinic acid, IgM responses to 3-OH-kynurenine and kynurenic acid, and impairments in Word List Memory and Verbal Fluency Tests and Mini-Mental State Examination. Nevertheless, nondeficit schizophrenia was not significantly separated from controls. The results show that schizophrenia is not a unitary disease with mere continuous differences in severity of illness between apparent subtypes. Deficit schizophrenia is a qualitatively distinct class defined by neuroimmune (autoimmune responses to TRYCATs) and neurocognitive (episodic and semantic memory) features coupled or not with clinical (negative) symptoms.

Entities:  

Keywords:  Compensatory anti-inflammatory reflex system; Cytokines; Immune activation; Inflammation; Schizophrenia; Tryptophan

Mesh:

Substances:

Year:  2018        PMID: 29527624     DOI: 10.1007/s11011-018-0208-4

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  28 in total

1.  Eugen Bleuler's concepts of psychopathology.

Authors:  Roland Kuhn
Journal:  Hist Psychiatry       Date:  2004-09

2.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

3.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

4.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

5.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

6.  Clinical subtypes of unipolar depression: Part III. Quantitative differences in various biological markers between the cluster-analytically generated nonvital and vital depression classes.

Authors:  M Maes; L Maes; C Schotte; M Vandewoude; M Martin; P D'Hondt; P Blockx; S Scharpé; P Cosyns
Journal:  Psychiatry Res       Date:  1990-10       Impact factor: 3.222

7.  Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old.

Authors:  M S Beeri; J Schmeidler; M Sano; J Wang; R Lally; H Grossman; J M Silverman
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

8.  The psychiatric symptomatology of deficit schizophrenia: a meta-analysis.

Authors:  Alex S Cohen; Laura A Brown; Kyle S Minor
Journal:  Schizophr Res       Date:  2009-11-03       Impact factor: 4.939

9.  A clinical and biological validation of the DSM-III melancholia diagnosis in men: results of pattern recognition methods.

Authors:  M Maes; L Maes; C Schotte; P Cosyns
Journal:  J Psychiatr Res       Date:  1992-07       Impact factor: 4.791

10.  Toward the future of psychiatric diagnosis: the seven pillars of RDoC.

Authors:  Bruce N Cuthbert; Thomas R Insel
Journal:  BMC Med       Date:  2013-05-14       Impact factor: 8.775

View more
  9 in total

1.  Development of a Novel Neuro-immune and Opioid-Associated Fingerprint with a Cross-Validated Ability to Identify and Authenticate Unknown Patients with Major Depression: Far Beyond Differentiation, Discrimination, and Classification.

Authors:  Hussein Kadhem Al-Hakeim; Suhaer Zeki Al-Fadhel; Arafat Hussein Al-Dujaili; Andre Carvalho; Sira Sriswasdi; Michael Maes
Journal:  Mol Neurobiol       Date:  2019-05-23       Impact factor: 5.590

2.  The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Authors:  Hussein Kadhem Al-Hakeim; Abbas F Almulla; Michael Maes
Journal:  Neurotox Res       Date:  2020-01-08       Impact factor: 3.911

3.  Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function.

Authors:  Li-Hong Pan; Ming Qian; Weihua Qu; Qin Tang; Yuzhong Yan
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-01       Impact factor: 2.570

4.  Subtyping schizophrenia based on symptomatology and cognition using a data driven approach.

Authors:  Luis Fs Castro-de-Araujo; Daiane B Machado; Maurício L Barreto; Richard Aa Kanaan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-07-15       Impact factor: 2.493

5.  Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnestic mild cognitive impairment.

Authors:  Buranee Kanchanatawan; Sookjaroen Tangwongchai; Thitiporn Supasitthumrong; Sira Sriswasdi; Michael Maes
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

Review 6.  How to construct neuroscience-informed psychiatric classification? Towards nomothetic networks psychiatry.

Authors:  Drozdstoy Stoyanov; Michael Hj Maes
Journal:  World J Psychiatry       Date:  2021-01-19

7.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

8.  False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway Classes.

Authors:  Michael Maes; George Anderson
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

9.  Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study.

Authors:  Maria Juncal-Ruiz; Laura Riesco-Davila; Javier Vazquez-Bourgon; Victor Ortiz-Garcia de la Foz; Jacqueline Mayoral-Van Son; Rosa Ayesa-Arriola; Esther Setien-Suero; Juan Carlos Leza; Marcos Lopez-Hoyos; Benedicto Crespo-Facorro
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.